BioArctic

BioArctic Treasury Stock

The Treasury Stock of BioArctic (BIOA B.ST) as of Nov 9, 2026 is 613.11 M SEK. In the previous year, Treasury Stock was 587.10 M SEK — a change of 4.43% (higher).

Treasury Stock

613.11 MSEK

YoY

4.43%

Last updated:

Treasury Stock of BioArctic is 2025 613.11 M SEK. Treasury Stock of BioArctic was 2024 587.10 M SEK. It decreases by 4.43% higher compared to the previous year.

The BioArctic Treasury Stock history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Treasury Stock
Date
Treasury Stock
Jan 1, 2018
560.02 M SEK
Jan 1, 2019
560.02 M SEK
Jan 1, 2020
560.02 M SEK
Jan 1, 2021
560.02 M SEK
Jan 1, 2022
566.00 M SEK
Jan 1, 2023
580.98 M SEK
Jan 1, 2024
587.10 M SEK
Jan 1, 2025
613.11 M SEK
The BioArctic Treasury Stock history
YEARTreasury StockYoY
613.11 MSEK+4.43%
587.10 MSEK+1.05%
580.98 MSEK+2.65%
566.00 MSEK+1.07%
560.02 MSEK0.00%
560.02 MSEK0.00%
560.02 MSEK0.00%
560.02 MSEK0.00%
560.02 MSEK+186,572.67%
300,000.00SEK-68.68%
958,000.00SEK—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

BioArctic Stock analysis

What does BioArctic do? BioArctic AB is a Swedish biotechnology company founded in 2003. The company is based in Stockholm and focuses on the development of innovative therapeutics for nervous system diseases such as Alzheimer's, Parkinson's, and spinal cord injuries. The company uses its expertise in biological and chemical drug research to discover and develop new therapeutic possibilities, with a focus on Amyloid-Beta production. BioArctic's business strategy is based on partnerships with pharmaceutical and biotech companies worldwide, working closely with partners to develop therapies and products that meet the needs and expectations of patients and doctors. BioArctic conducts research in three different areas: Alzheimer's, Parkinson's, and spinal cord injuries. The company works with partners such as Nutricia, Eisai, Just Biotherapeutics, Abcam, Neuropharm, AbbVie, Q-Med, Uppsala University, and the Karolinska Institute to develop treatments for these conditions. BioArctic has already brought several promising products to market, including BAN2401 for Alzheimer's and SC0806 for spinal cord injuries. Overall, BioArctic is a leading company in biological and chemical drug research, with a focus on developing new therapies and products for the benefit of patients and doctors worldwide. BioArctic is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BioArctic stock

Treasury Stock of BioArctic is 613.11 M SEK in 2025.

Treasury Stock of BioArctic changed from 587.10 M SEK to 613.11 M SEK, representing a 4.43% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Treasury Stock BioArctic since 2006 – with annual values, charts, and detailed analysis.

Treasury stock represents shares that were repurchased by the company. It reduces shareholders' equity and outstanding share count.

Treasury Stock's SEK is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Treasury Stock's BioArctic historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — BioArctic

All Key Metrics — BioArctic